San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, AnaBios is raising $6,499,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Andre Ghetti played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AnaBios
AnaBios generates highly valuable, predictive human data in advance of clinical trials, ensuring the selection of the most effective and safest drugs, thereby reducing the time and expense related to clinical trial failures. Through its proprietary technology, based on the use of human donor organs and tissues, AnaBios studies ex-vivo human responses to drugs and further investigates the molecular and functional basis of relevant human physiology. AnaBioss research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease and neurodegeneration. AnaBios partners and works with global Fortune 500 pharmaceutical companies, CROs and universities. Located in San Diego, California, AnaBios markets its products and services directly, as well as through distributors and partners worldwide. AnaBios also drives an internal drug discovery platform via in-licensed programs from partners in the pharmaceutical industry and academia.

To learn more about AnaBios, visit http://www.anabios.com/

Contact:
Andre Ghetti, Chief Executive Officer
858-224-7371
https://www.linkedin.com/in/andre-ghetti-513a8b52/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved